

Published in final edited form as:

Nat Genet. 2014 April ; 46(4): 385–388. doi:10.1038/ng.2917.

Mutations in the DNA methyltransferase gene, *DNMT3A*, cause an overgrowth syndrome with intellectual disability

Katrina Tatton-Brown^{1,2,3}, Sheila Seal¹, Elise Ruark¹, Jenny Harmer⁴, Emma Ramsay¹, Silvana del Vecchio Duarte¹, Anna Zachariou¹, Sandra Hanks¹, Eleanor O'Brien¹, Lise Aksglaede⁵, Diana Baralle⁶, Tabib Dabir⁷, Blanca Gener⁸, David Goudie⁹, Tessa Homfray³, Ajith Kumar¹⁰, Daniela T Pilz¹¹, Angelo Selicorni¹², I Karen Temple⁶, Lionel Van Maldergem¹³, Naomi Yachevich¹⁴, The Childhood Overgrowth Consortium¹⁵, Robert van Montfort⁴, and Nazneen Rahman^{1,2}

¹Division of Genetics and Epidemiology, the Institute of Cancer Research, London, UK ²Cancer Genetics Unit, Royal Marsden Hospital, London, UK ³Medical Genetics, St George's University of London, London, UK ⁴Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK ⁵Department of Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark ⁶Human Genetics and Genomic Medicine, Faculty of Medicine, University of Southampton, Southampton, UK ⁷Northern Ireland Regional Genetics Centre, Clinical Genetics Service, Belfast City Hospital, Belfast, Northern Ireland ⁸Servicio de Genética, BioCruces Health Research Institute, Hospital Universitario Cruces, Bizkaia, Spain ⁹Department of Human Genetics, Ninewells Hospital and Medical School, Dundee, UK ¹⁰North East Thames Regional Genetics Service, Great Ormond St. Hospital, London, UK ¹¹Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK ¹²Ambulatorio Genetica Clinica Pediatrica, Clinical Pediatrica Università Milano Bicocca, Fondazione MBBM, AO S Gerardo, Monza, Italy ¹³Centre de Genetique Humaine, Université de Franche-Comte, Besancon 25030, France ¹⁴Clinical Genetics Services, NYU Hospitals Center, New York University, New York, USA

Abstract

Overgrowth disorders are a heterogeneous group of conditions characterised by increased growth parameters and variable other clinical features, such as intellectual disability and facial dysmorphism¹. To identify novel causes of human overgrowth we performed exome sequencing in

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to NR (rahmanlab@icr.ac.uk) or KT-B (kate.tatton-brown@icr.ac.uk).

¹⁵A full list of members is provided in the Supplementary Note

Author Contributions

S.S. E.R. S.dVD. S.H. E.O.B. undertook the molecular analyses. E.R. undertook the bioinformatics analyses. A.Z. coordinated recruitment. L.A., D.B., T.D., B.G., D.G., T.H., A.K., D.P., A.S., I.K.T., L.V.M., N.Y. and K.T-B. collected samples and undertook phenotyping. J.H. and R.V.M. undertook the protein modelling N.R. and K.T-B. designed and oversaw the project and wrote the paper with input from other authors.

Accession numbers

DNMT3A mutation nomenclature corresponds to Ensembl Transcript ID ENST00000264709.

Competing Financial Interests

None

10 proband-parent trios and detected two *de novo* *DNMT3A* mutations. We identified 11 additional *de novo* mutations through *DNMT3A* sequencing of a further 142 individuals with overgrowth. The mutations were all located in functional *DNMT3A* domains and protein modelling suggests they interfere with domain-domain interactions and histone binding. No similar mutations were present in 1000 UK population controls (13/152 vs 0/1000; $P < 0.0001$). Mutation carriers had a distinctive facial appearance, intellectual disability and increased height. *DNMT3A* encodes a key methyltransferase essential for establishing the methylation imprint in embryogenesis and is commonly somatically mutated in acute myeloid leukaemia²⁻⁴. Thus *DNMT3A* joins an emerging group of epigenetic DNA and histone modifying genes associated with both developmental growth disorders and haematological malignancies⁵.

The control of human growth is highly complex and influenced by common and rare genetic variation⁶. The study of human overgrowth syndromes, which are characterised by increased prenatal and postnatal growth relative to age-related peers, has led to significant insights into fundamental biological processes involved in growth control¹. As many growth disorders present as non-familial cases with a distinctive phenotype we hypothesised that *de novo* gene mutations may underlie some cases. To investigate this we are conducting trio-based exome sequencing in individuals with overgrowth and their parents using the Illumina TruSeq exome enrichment array. We are performing sequencing with an Illumina HiSeq 2000, aligning the data with Stampy, performing variant calling with Platypus, variant annotation with SAVANT and identifying potential *de novo* variants using a custom R script.

Review of the first 10 trios revealed two with apparent *de novo* mutations in *DNMT3A* (DNA cytosine 5 methyltransferase 3A), which was of immediate interest because of the functional relationship of this gene with *EZH2*, a known overgrowth predisposition gene we previously identified as the cause of Weaver syndrome^{7,8}. By Sanger sequencing we confirmed the mutations, an inframe deletion p.Trp297del in COG0274 and a nonsynonymous mutation, p.Leu648Pro in COG0553, were present in the proband but not in the parents (Table 1, Supplementary Figure 1).

To further evaluate the role of *DNMT3A*, we sequenced the full coding sequence and intron-exon boundaries of the gene by Sanger sequencing in a further 142 individuals with overgrowth in whom mutations in *NSD1*, *EZH2* and *PTEN* and dysregulation of the 11p15 growth regulatory region had been excluded, and for whom parental DNA was also available (Supplementary Table 1). We identified an additional 11 *de novo* *DNMT3A* mutations. Thus in total, we found 13 different *de novo* *DNMT3A* mutations in 152 individuals with overgrowth phenotypes: 10 nonsynonymous mutations, two small frameshifting insertions and one inframe deletion (Figure 1, Table 1, Supplementary Figure 1). These data establish *DNMT3A* mutations as a cause of a novel human disorder, which we have termed 'DNMT3A overgrowth syndrome'.

A consistent phenotype, characterised by a distinctive facial appearance, tall stature and intellectual disability, was evident amongst the thirteen individuals with *de novo* *DNMT3A* mutations (Figure 2, Table 1). The facial gestalt was characterised by a round face, heavy, horizontal eyebrows and narrow palpebral fissures (Figure 2). Height was increased in all

individuals ranging from 1.8 to 4.2 (mean 3.0) standard deviations above the mean. Head circumference was also increased ranging from 1.2 to 5.1 (mean 2.5) standard deviations above the mean. Intellectual disability, which was described as moderate in 11 individuals and mild in the remaining two, is also a key feature of the condition. Other, less frequent clinical features were variably present (Table 1). More detailed phenotyping in larger series are required to evaluate if these are real associations of *DNMT3A* mutations and to better define the clinical spectrum of this new overgrowth syndrome.

In eukaryotic DNA, methylation preferentially occurs at cytosine bases which are converted to 5-methylcytosine by four DNA methyltransferase enzymes: DNMT3A, DNMT3B, DNMT1 and DNMT3L². DNMT3A and DNMT3B are essential for the establishment of new methylation marks following erasure of parental methylation patterns during early embryonic development and for the establishment of sex-dependent methylation marks of imprinted genes during gametogenesis⁹⁻¹¹. By contrast, DNMT1 is essential for the maintenance and conservation of DNA methylation marks after DNA replication¹⁰. DNMT3L does not possess inherent enzymatic activity but appears to physically interact with DNMT3A and stimulate its enzymatic activity¹²⁻¹⁴.

DNMT3A contains three functional domains: a proline-tryptophan-tryptophan-proline (PWWP) domain; an ATRX-DNMT3A-DNMT3L-type zinc finger (ADD) domain and a C terminal DNA methyltransferase domain (Figure 1). It is noteworthy that all the mutations we identified were located in these domains. None were present in 1000 exomes from a UK population control series that were sequenced and analysed in a similar fashion. Moreover, no other frameshifting or nonsynonymous mutations in domains were present in the control exomes; four nonsynonymous variants were detected, but all were outside the functional domains (Figure 1). These data provide further evidence that the *DNMT3A* mutations in cases are pathogenic (13/152 vs 0/1000, $P < 0.0001$).

DNMT3A is one of the most frequently mutated genes in acute myeloid leukemia (AML)^{3,4,15}. Somatic *DNMT3A* mutations are detected in approximately one third of cytogenetically normal AML and have also been reported in other haematological neoplasms, such as myelodysplasia (MDS)^{16,17}. Over half the somatic *DNMT3A* mutations target a single residue, Arg882, with the remainder being nonsynonymous and truncating mutations scattered through the gene^{3,15}. The somatic mutational spectra thus differs from the *de novo* mutations we identified in overgrowth cases; we did not detect any Arg882 mutations and only two of the mutations we report, Arg749Cys and Pro904Leu, are also in the 167 confirmed somatic *DNMT3A* mutations in haematological malignancies in the COSMIC database (Supplementary Table 2).

Protein structure modelling suggests the Arg882 somatic mutations affect DNA binding and functional analyses demonstrate mutations at this residue result in reduced methyltransferase activity, possibly through a dominant-negative mechanism^{4,15,18}. To explore the potential impact of the *DNMT3A* overgrowth mutations we undertook protein structure modelling which revealed the residues targeted by nonsynonymous mutations in the MTase domain appear to be located at the interaction interface with the ADD domain, whereas those in the ADD domain are close to the histone H3 binding region (Figure 3). The Arg767 residue in

the MTase domain that is mutated by a frameshifting insertion is situated at the interface between DNMT3A and DNMT3L. Thus, whilst none of the overgrowth mutations appear likely to affect DNA binding, their position and the role of the ADD domain in the recognition of unmethylated lysine 4 of histone H3 suggest they may interfere with domain-domain interactions and histone binding, thereby disrupting *de novo* methylation¹⁹.

Taken together these data are intriguing as they show both clear differences and some overlap between the *DNMT3A* mutational spectra in malignancies and overgrowth. The mechanism of pathogenesis in DNMT3A overgrowth syndrome is currently unclear though a simple haploinsufficiency model appears unlikely given the small proportion of truncating mutations. Of note, parents of *Dnmt3a* knockout mice are grossly phenotypically normal, though it is unclear whether this is because loss of function of one *Dnmt3a* copy is not associated with overgrowth, or because the overgrowth phenotype is too subtle to detect in mice⁹. Further functional and mutational analyses will be of interest, to extend and illuminate these observations. Long-term follow-up of individuals with DNMT3A overgrowth syndrome, with particular focus on cancer incidence, will also be of interest. To date, none of the probands have developed malignancies, though the oldest is only 29 years of age. Haematological malignancies with somatic *DNMT3A* mutations typically occur in middle-aged individuals^{3,4}, and it is thus possible that an increased cancer risk only manifests at older ages.

DNMT3A joins an emerging family of genes with dual roles in the pathogenesis of syndromic overgrowth and myeloid neoplasms. Other similar genes include *EZH2* and *NSD1*⁵. The overgrowth phenotypes associated with *EZH2* and *NSD1* constitutional mutations, which are called Weaver and Sotos syndrome respectively, are similar to each other and to DNMT3A overgrowth syndrome^{5,8,20}. Somatic *EZH2* mutations, both activating and inactivating, occur in AML and poor prognosis myeloproliferative neoplasms and myelodysplastic syndromes^{15,21}. Somatic *NSD1* point mutations are rare⁴ but the NUP90-NSD1 fusion protein, generated through the recurrent translocation, t(5;11)(q35.3;p15.5) is present in approximately 5% of childhood acute myeloid leukaemia²². Both *EZH2* and *NSD1* are histone methyltransferases that play key roles in regulation of transcription through histone modification and chromatin modelling. *EZH2* catalyses the trimethylation of lysine residue 27 in histone H3 (H3K27me3) and is associated with transcriptional repression, whereas *NSD1* preferentially catalyses methylation of lysine residue 36 of histone H3 (H3K36) and is primarily associated with transcriptional activation^{23,24}. Of note, another gene involved in chromatin modification that is often mutated in AML and MDS, *ASXL1*, is also associated with a growth disorder^{15,25}. Constitutional *de novo* truncating *ASXL1* mutations cause Bohring-Opitz syndrome, a rare disorder characterised by severe undergrowth, severe intellectual disability, a characteristic facial appearance and flexion deformities²⁵. This suggests other epigenetic regulatory genes somatically mutated in haematological malignancies, such as *TET2*, *IDH1* and *IDH2* would be worth evaluating in developmental growth disorders¹⁵.

METHODS

Patient samples

Individuals with overgrowth were recruited through the Childhood Overgrowth Study. The research has approval from the London Multicentre Ethics Committee (Reference: MREC/01/2/44) and informed consent was obtained from all participants and/or families. DNA was extracted from peripheral blood and was available from all probands and their parents. Detailed phenotypic information, through a standardised questionnaire and photographs was also obtained. Specific consent to publish facial photographs was obtained. A full list of collaborators is given in the Supplementary Note.

Control samples

We used lymphocyte DNA from 1000 population-based controls obtained from the 1958 Birth Cohort Collection, a continuing follow-up of persons born in the United Kingdom in one week in 1958. Biomedical assessment was undertaken during 2002-2004 at which blood samples and informed consent were obtained for creation of a genetic resource. <http://www.cls.ioe.ac.uk/>

Exome sequencing

We prepared DNA libraries from 1.5 µg blood-derived genomic DNA using the Paired-End DNA Sample Preparation Kit (Illumina). DNA was fragmented using Covaris technology and the libraries were prepared without gel size selection. We performed target enrichment using the TruSeq Exome Enrichment Kit (Illumina) targeting 62 Mb of the human genome. The captured DNA libraries were PCR amplified using the supplied paired-end PCR primers. Sequencing was performed with an Illumina HiSeq2000 generating 2 × 101 bp reads.

Exome variant calling and de novo mutation detection

We mapped sequencing reads to the human reference genome (hg19) using Stampy version 1.0.14²⁶. Duplicate reads were flagged using Picard version 1.60 (<http://picard.sourceforge.net>). Median coverage of the target at 15× was 91% across the 1030 individuals (1000 controls and 30 individuals from the 10 overgrowth trios), with a median of 47,215,315 reads mapping to the target. We used Platypus version 0.1.5 to perform variant calling²⁷ and SAVANT, a custom strand-aware variant annotation tool written in Python which follows HGVS nomenclature and ensures consistent annotation of indels, shifting them to their most 3' position in the transcript. This script is available on request. We used an R script to identify variants present in cases but not either parent which is available on request.

DNMT3A mutation analysis

We performed Sanger sequencing of PCR products from genomic DNA to confirm the mutations identified by exome sequencing, and to mutationally analyse the gene in the overgrowth series. We designed PCR primers to amplify the 22 coding exons and intron-exon boundaries of *DNMT3A* in 4 multiplex PCR reactions (Supplementary Table 1). The

PCR was carried out using a Qiagen Multiplex PCR kit according to the manufacturer's instructions. Products were sequenced with the original PCR primers or internal sequencing primers (exons 3, 6, 8, 10, 14 and 22) using the BigDye Terminator Cycle Sequencing Kit and an ABI 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequences were analyzed using Mutation Surveyor software v3.97 (SoftGenetics, State College, PA, USA), and verified by manual inspection. All mutations were confirmed by bidirectional sequencing of a second, independently amplified PCR product.

Statistical Analysis

The frequency of mutations in cases and controls was compared using a two-sided Fisher's exact test.

Protein structure modelling of mutations

The model of the DNMT3A-DNMT3L complex was created using the crystal structures of the DNMT3A ADD domain (PDB 3A1B), the DNMT3A MTase domain (PDB 2QRV) and full length DNMT3L (PDB 2PVC). The bound DNA was positioned by superposing the crystal structure of bacterial cytosine methyltransferase HhaI in complex with DNA (PDB 1MHT). First, the structure of partial DNMT3L in complex with DNMT3A was superposed onto the structure of full-length DNMT3L to reveal the interactions of the full length DNMT3L with DNMT3A. Subsequently, the ADD domain of DNMT3A was positioned by superposing it onto the homologous region of the second molecule of full-length DNMT3L. Finally, the DNA was positioned by superposing the crystal structure of bacterial cytosine methyltransferase HhaI in complex with DNA onto the MTase domain of DNMT3A, placing the DNA at the SAM/DNA binding region. The image was depicted using PyMOL visualization software (The PyMOL Molecular Graphics System, Version 1.6.0.0 Schrödinger, LLC.).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the families for their participation in our research and the physicians and nurses that recruited them. Samples were collected through the Childhood Overgrowth Collaboration; a full list of collaborators in on the Supplementary Note. We are grateful to Margaret Warren-Perry, Darshna Dudakia and Jess Bull for assistance in recruitment, and to Ellen Moran (Department of Genetics, NYU Hospital for Joint Diseases, New York, USA) and Alexandra Murray (Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK) for their clinical input for COG1770 and COG109 respectively. We thank Ann Strydom for assistance in preparing the manuscript. We are grateful to Dr Gerton Lunter and Dr Márton Münz (Wellcome Trust Centre for Human Genetics) Oxford University) for their contribution to the development of the custom annotation tool SAVANT. We acknowledge use of services provided by the Institute of Cancer Research Genetics Core Facility, which is managed by Sandra Hanks and Nazneen Rahman. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. We also thank Mariani Foundation Milan for supporting the clinical activity of UOS Genetica Clinica Pediatrica, Fondazione MBBM, AO S Gerardo Monza, Italy. This research and was supported by the Wellcome Trust (100210/Z/12/Z) and the Institute of Cancer Research, London.

References

1. Tatton-Brown K, Weksberg R. Molecular mechanisms of childhood overgrowth. *Am J Med Genet C Semin Med Genet.* 2013; 163:71–5. [PubMed: 23606607]
2. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. *Chembiochem.* 2011; 12:206–22. [PubMed: 21243710]
3. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. *N Engl J Med.* 2010; 363:2424–33. [PubMed: 21067377]
4. Yan XJ, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. *Nat Genet.* 2011; 43:309–15. [PubMed: 21399634]
5. Tatton-Brown K, Rahman N. The NSD1 and EZH2 Overgrowth Genes, Similarities and Differences. *Am J Med Genet C Semin Med Genet.* 2013; 163:86–91. [PubMed: 23592277]
6. Durand C, Rappold GA. Height matters-from monogenic disorders to normal variation. *Nat Rev Endocrinol.* 2013; 9:171–7. [PubMed: 23337954]
7. Rush M, et al. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. *Epigenetics.* 2009; 4:404–14. [PubMed: 19717977]
8. Tatton-Brown K, et al. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. *Oncotarget.* 2011; 2:1127–33. [PubMed: 22190405]
9. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell.* 1999; 99:247–57. [PubMed: 10555141]
10. Smallwood SA, Kelsey G. De novo DNA methylation: a germ cell perspective. *Trends Genet.* 2012; 28:33–42. [PubMed: 22019337]
11. Kaneda M, et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. *Nature.* 2004; 429:900–3. [PubMed: 15215868]
12. Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. *Proc Natl Acad Sci U S A.* 2002; 99:16916–21. [PubMed: 12481029]
13. Hata K, Okano M, Lei H, Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. *Development.* 2002; 129:1983–93. [PubMed: 11934864]
14. Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. *J Biol Chem.* 2004; 279:27816–23. [PubMed: 15105426]
15. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. *Blood.* 2013; 121:3563–72. [PubMed: 23640996]
16. Marcucci G, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. *J Clin Oncol.* 2012; 30:742–50. [PubMed: 22291079]
17. Nikoloski G, van der Reijden BA, Jansen JH. Mutations in epigenetic regulators in myelodysplastic syndromes. *Int J Hematol.* 2012; 95:8–16. [PubMed: 22234528]
18. Kim SJ, et al. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. *Blood.* 2013; 122:4086–89. [PubMed: 24167195]
19. Otani J, et al. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. *EMBO Rep.* 2009; 10:1235–41. [PubMed: 19834512]
20. Tatton-Brown K, et al. Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. *Am J Hum Genet.* 2005; 77:193–204. [PubMed: 15942875]
21. Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. *Leukemia.* 2013; 28:44–49. [PubMed: 24097338]
22. Cerveira N, et al. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. *Leukemia.* 2003; 17:2244–7. [PubMed: 12931227]

23. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. *Curr Opin Genet Dev.* 2004; 14:155–64. [PubMed: 15196462]
24. Morishita M, di Luccio E. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1. *Biochem Biophys Res Commun.* 2011; 412:214–9. [PubMed: 21806967]
25. Hoischen A, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. *Nat Genet.* 2011; 43:729–31. [PubMed: 21706002]
26. Lunter G, Goodson. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. *Genome Res.* 2011; 21:936–9. [PubMed: 20980556]
27. Rimmer, A.; Lunter, G.; McVean, G. Platypus: an integrated variant caller. 2012. www.well.ox.ac.uk/platypus




Figure 1. DNMT3A structure and mutations. Schematic representation of the protein structure of DNMT3A with (a) *de novo* mutations identified in overgrowth cases placed above the protein and (b) nonsynonymous variants identified in controls placed below the protein.




Figure 2.

Characteristic facial appearance DNMT3A overgrowth syndrome.

The mutation, growth parameters and other clinical features are given in Table 1 under the appropriate COG ID: **(a)** COG1288; **(b)** COG1670; **(c)** COG0422; **(d)** COG1695; **(e)** COG1688; **(f)** COG0109; **(g)** COG0553; **(h)** COG1512. Specific consent to publish facial photographs was obtained for all individuals.




Figure 3.

Mutations mapped onto a structural model of the DNMT3A-DNMT3L complex. Two orientations of a model of the DNMT3A monomer generated by superposition of structures of the DNMT3A ADD domain (cyan), the DNMT3A MTase domain (light orange) and full-length DNMTL (green) show mutations in the MTase domain in purple and mutations in the ADD domain in pink. The histone peptide bound to the ADD domain is shown in orange and the position of the DNA is inferred by superposition of the structurally homologous bacterial cytosine methyltransferase HhaI-DNA complex. The model shows that the mutations in the MTase domain appear to be located at the interaction interface with its ADD domain and at the interface with DNMT3L. Mutations in the ADD domain are close to the histone-binding region.

Table 1

DNMT3A mutations and associated clinical features

Case ID	Mutation	Protein alteration	Height /sd	OFC /sd	Age* /yrs	Intellectual disability	Other clinical features
COG0274	c.889_891delITGG	p.Trp297del	2.6	2.2	3.0	moderate	Seizures
COG1770	c.929T>A	p.Trp297del	2.9	3.7	9.0	moderate	Ventriculomegaly, umbilical hernia, scoliosis
COG1670	c.934_937dupTCTT	p.Trp297del	3.2	2.8	20.5	moderate	
COG0141	c.1594G>A	p.Trp297del	2.3	na	5.9	moderate	
COG0422	c.1643T>A	p.Met548Lys	1.9	1.2	4.1	moderate	Atrio-septal defect
COG1288	c.1645T>C	p.Cys549Arg	1.8	3.8	11.3	moderate	Atrio-septal defect, sagittal craniosynostosis
COG0553	c.1943T>C	p.Leu648Pro	3.4	5.1	19.0	mild	Mild hemihypertrophy, umbilical hernia
COG1688	c.2099C>T	p.Pro700Leu	2.8	2.1	13.0	moderate	Scoliosis
COG1695	c.2245C>T	p.Arg749Cys	4.0	3.8	12.0	moderate	Vesico-ureteric reflux, patella subluxation
COG1512	c.2297dupA	p.Arg767fs	3.8	1.6	8.2	moderate	
COG1771	c.2512A>G	p.Asn838Asp	4.2	1.7	13.4	mild	Testicular atrophy, seizures, scoliosis
COG0109	c.2705T>C	p.Phe902Ser	2.7	1.3	9.8	moderate	Mitral and tricuspid regurgitation, kyphoscoliosis
COG1677	c.2711C>T	p.Pro904Leu	3.7	1.2	11.0	moderate	

Abbreviations: sd, standard deviations with reference to the mean (UK90 growth data); na, not available

* This is the age at which growth parameters were measured.